Bearish
1
Neutral
6
Bullish
7
Bearish
6
Neutral
6
Bullish
34
Bearish
5
Neutral
0
Bullish
27
| Company | Weightage (%) |
| Sun Pharmaceutical Industries Limited | 21.42% |
| Divi's Laboratories Limited | 9.53% |
| Dr. Reddy's Laboratories Limited | 8.93% |
| Cipla Limited | 8.86% |
| Lupin Limited | 6.18% |
| Laurus Labs Limited | 5.96% |
| Torrent Pharmaceuticals Limited | 5.19% |
| Aurobindo Pharma Limited | 4.48% |
| Glenmark Pharmaceuticals Limited | 3.85% |
| Alkem Laboratories Limited | 3.62% |
1,570
0.18%
0.02%
37.6
Low Risk
0.15
0.67%
21.70
30.28
0.949
—
Bullish
57.16
27.94
25.97
Allocation
The current market price of Nippon India NIFTY Pharma ETF Growth Plan is ₹29.06. ETF prices fluctuate during market hours based on demand, supply, and movements in the underlying index or assets.
Nippon India NIFTY Pharma ETF Growth Plan, managed by Nippon Life India Asset Management Limited, is a passive equity ETF seeking to replicate or track the Nifty Pharma TRI. The scheme follows a passive benchmark-oriented approach against the Nifty Pharma TRI; Jitendra Tolani has managed it since February 2025, bringing 19 years of stated experience to oversight. Portfolio exposure is entirely represented by Pharmaceuticals & Biotechnology holdings, with Sun Pharmaceutical Industries leading at 21.4%; the top four positions collectively account for 48.7%, highlighting concentration. Performance recorded a 1Y return of 12.2%. As of May 2026, assets stood at ₹1,570.2 Cr versus a ₹1,520.4 Cr monthly average; expense ratio was 0.2%, and tracking error 0.0%.
Nippon India NIFTY Pharma ETF Growth Plan is designed to track Nifty Pharma TRI, allowing investors to gain exposure to its underlying securities through a single investment.
The expense ratio of Nippon India NIFTY Pharma ETF Growth Plan is 0.18%. This represents the annual fee charged by the fund house for managing the ETF and is deducted from the fund’s assets.
The Assets Under Management (AUM) of Nippon India NIFTY Pharma ETF Growth Plan is approximately ₹1,570.17. AUM reflects the total market value of assets managed by the ETF and is often used as an indicator of fund size and liquidity.
Nippon India NIFTY Pharma ETF Growth Plan is classified under the as per the risk-o-meter defined by the fund house risk category. The risk level depends on the volatility of the underlying index, market conditions, and asset composition of the ETF.
The tracking error of Nippon India NIFTY Pharma ETF Growth Plan is 0.02%. Tracking error measures how closely the ETF’s performance matches its benchmark index over time.
Nippon India NIFTY Pharma ETF Growth Plan has a dividend yield of 0.67%. Dividend treatment depends on the ETF structure and fund house policy.
Based on available data, Nippon India NIFTY Pharma ETF Growth Plan has delivered the following returns: 1-year return: 25.10%. 3-year return: 79.16%. 5-year return: 114.62%. Past performance does not guarantee future results.
Before investing in Nippon India NIFTY Pharma ETF Growth Plan, investors generally consider the underlying index, expense ratio, tracking error, risk profile, liquidity, and how the ETF fits within their overall portfolio strategy.

AUM
₹ 1,570 Cr
Expense Ratio
0.18%
Performance
STEADY PERFORMER
Technicals
Bullish
Risk
—
Liquidity
GOOD
Consistency
GOOD
136.94
▲ 0.00%
42.58
▲ 0.76%
137.44
▲ 0.90%
160.33
▲ 0.60%
146.75
▼ 3.96%
294.10
▲ 1.20%
297.69
▲ 0.81%
1000.01
▲ 0.00%
149.03
▲ 1.13%
466.70
▲ 0.32%
66.11
▲ 0.00%
281.34
▲ 0.63%
669.10
▲ 2.52%
35.00
▲ 1.80%
424.77
▲ 0.29%
29.86
▲ 0.78%
110.19
▲ 1.08%
78.25
▲ 0.12%
234.81
▼ 0.11%
91.20
▼ 0.37%
101.89
▼ 4.16%
998.35
▲ 0.88%
962.34
▲ 0.82%
1065.48
▲ 0.04%
29.06
▼ 0.03%
790.65
▲ 0.36%